Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31317 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL14141983 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL5120356 | 1.00 | HSD11B1 (0.43) | HSD11B1KMT2AALDH1A1HSP90AA1P2RY2 | |
| SCHEMBL23524 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL29993001 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL14141639 | 0.87 | KMT2A (0.44) | KMT2AALDH1A1HSP90AA1P2RY2GPR17 | |
| SCHEMBL5672285 | 0.87 | TDP1 (0.40) | HSD11B1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL7495927 | 0.87 | TDP1 (0.40) | HSD11B1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL7490542 | 0.85 | TDP1 (0.43) | HSD11B1KMT2AALDH1A1LMNASLC1A3 | |
| SCHEMBL5671784 | 0.85 | TDP1 (0.43) | HSD11B1KMT2AALDH1A1LMNASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2003-11-06 | — | — | US | claimed |
| EP-1021449-B1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | claimed |
| EP-1021449-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018110-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-04-15 | — | — | WO | claimed |
| WO-2023202383-A1 | TETRAHYDROTHIENOPYRIDINE DEUTERATED DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中荣凯特（北京）生物科技有限公司 | 2023-10-26 | — | — | WO | disclosed |
| EP-3674306-B1 | THIENOPYRIDINE DERIVATIVES CONTAINING AN ETHYLENIC ESTER, PREPARATION METHOD THEREFOR AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-116621856-A | Novel carbamate compound and application thereof | 成都施贝康生物医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116621857-A | Novel carbamate compound and application thereof | 成都施贝康生物医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-114736215-B | Tetrahydrothienopyridine deuterated derivative and preparation method and pharmaceutical application thereof | 中荣凯特（北京）生物科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-114736215-A | Tetrahydrothienopyridine deuterated derivative and preparation method and pharmaceutical application thereof | 中荣凯特（北京）生物科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-112851570-A | Preparation method and medical application of unsaturated cyclic amine cysteine disulfide derivative | 北京沃邦医药科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200361952-A1 | THIENOPYRIDINE DERIVATIVES CONTAINING UNSATURATED ALIPHATIC OLEFINIC BOND, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-1501838-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | Dinamite Dipharma S.p.A. (in abbreviated form Dipharma S.p.A.) (IT) | 2005-02-02 | — | — | EP | disclosed |
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2004-12-23 | — | — | US | disclosed |
| WO-2003093276-A1 | A PROCESS FOR THE PREPARATION OF CLOPIDOGREL | DIPHARMA S.P.A. (IT) | 2003-11-13 | — | — | WO | disclosed |
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6573381-B1 | Useful as intermediates, notably for the synthesis of methyl (S)-2(2-chlorophenyl)-2(4,5,6,7-tetrahydrothieno(3,2-c)-5-pyridyl)acetate or clopidrogel | SANOFI-SYNTHELABO (FR) | 2003-06-03 | — | — | US | disclosed |
| EP-1021449-B1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1021449-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018110-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361952-A1 | THIENOPYRIDINE DERIVATIVES CONTAINING UNSATURATED ALIPHATIC OLEFINIC BOND, PREPARATION METHOD AND USE THEREOF | PTGIR, TBXA2R, PTGER1 | HSD11B1 1378/4885KMT2A 2901/4885ALDH1A1 477/4885 |
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | HAAO, HTR3C, HTR3A | HSD11B1 53/4885KMT2A 417/4885ALDH1A1 414/4885 |
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | HAAO, HTR3C, HTR3A | HSD11B1 53/4885KMT2A 417/4885ALDH1A1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.